Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease

(2017) Megan Hohenberger et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks: Update and commentary

(2017) Yuan Yu Michael Huang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

(2017) I. Belinchón et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry

(2017) A. Egeberg et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

(2017) Kristin K Jørgensen et al.   LANCET

Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort

(2016) J. Zweegers et al.   BRITISH JOURNAL OF DERMATOLOGY

The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis

(2016) Paolo Dapavo et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

(2016) A. Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Biosimilars for psoriasis: preclinical analytical assessment to determine similarity

(2015) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis

(2015) Alexander Nast et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris

(2014) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

(2014) G. Carretero et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort

(2014) O. Ahlehoff et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost Effectiveness of Biologic Therapies for Plaque Psoriasis

(2013) Christine S. Ahn et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Biologic fatigue in psoriasis

(2013) Ethan C. Levin et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Which Antipsoriatic Drug Has the Fastest Onset of Action?—Systematic Review on the Rapidity of the Onset of Action

(2013) Alexander Nast et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

(2013) L. Puig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Pharmacological Undertreatment of Coronary Risk Factors in Patients with Psoriasis: Observational Study of the Danish Nationwide Registries

(2012) Ole Ahlehoff et al.   PLoS One

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

(2011) R. Gniadecki et al.   BRITISH JOURNAL OF DERMATOLOGY